13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation In vitro , cell culture and mouse studies identified an OGG1 inhibitor that could help treat pulmonary inflammation. Screening of a small molecule library via an in vitro activity assay, followed by optimization...
19:23 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Low esophageal levels of SPINK7 could help diagnose eosinophilic esophagitis. In esophageal tissue samples, SPINK7 protein and mRNA levels were lower in patients with eosinophilic esophagitis than in healthy volunteers, and the...
18:07 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a chemokine-targeting single-chain variable fragment (scFv)-based fusion protein that could help treat arthritis. Screening of a scFv library for binding to various human and mouse chemokines, engineering...
20:46 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Mucositis Mouse studies identified a carvacrol-based TRPA1 agonist that could help treat intestinal mucositis. In a mouse model of the disease, a previously identified carvacrol analog increased survival, body mass, leucocyte numbers in the...
21:43 , Sep 29, 2017 |  BC Week In Review  |  Financial News

GRO Biosciences launches with $2.1M seed funding

Synthetic protein newco GRO Biosciences Inc. (Boston, Mass.) raised $2.1 million on Sept. 28 in a seed round led by Digitalis Ventures and Innovation Endeavors. The newco spun out of Harvard Medical School Professor George...
20:22 , Sep 28, 2017 |  BC Extra  |  Company News

GRO Biosciences launches with $2.1M seed funding

Synthetic protein newco GRO Biosciences Inc. (Boston, Mass.) raised $2.1 million in a seed round led by Digitalis Ventures and Innovation Endeavors. The newco spun out of Harvard Medical School Professor George Church's lab with...
19:40 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Dermatology; inflammation

INDICATION: Dermatitis; allergy Cell culture and mouse studies suggest morpholino oligomers that exclude exon 3 from the FCER1B transcript could help treat allergy and allergic dermatitis. In activated primary mouse bone marrow-derived mast cells, a...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)

Cancer INDICATION: Prostate cancer Patient sample and mouse studies suggest inhibiting CXCL1- CXCR1 / CXCR2 signaling could help treat prostate cancer in obese patients. CXCL1 was highly expressed in tumor samples from 19 of 21...
07:00 , Sep 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interferon regulatory factor 5 (IRF5); chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA)

Inflammation INDICATION: Inflammation Mouse studies suggest inhibiting IRF5 could help treat inflammatory diseases. In a mouse model of antigen-induced arthritis, IRF5 knockout decreased knee swelling, synovial membrane thickening, synovial levels of neutrophil-recruiting CXCL1 and the...
08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Diagnostic markers of relapsing multiple sclerosis (MS)

Biomarkers TECHNOLOGY: Plasma markers Plasma levels of neutrophil-related proteins could help diagnose relapsing MS. In presymptomatic mouse models of experimental autoimmune encephalomyelitis, the numbers of disease-promoting neutrophils in the CNS and plasma, and levels of...